Accordingly, we sought to expand on previous modeling to determine disease prevalence, treatment distribution, and survival outcomes for patients with severe AS aged ≥60 years. Using a mixed methodology of meta-analysis and stochastic simulation, our analysis estimates the number of patients with severe AS eligible for AVR across 37 countries comprising the International Monetary Fund's 2015 advanced economies index. Key Words: aortic valve ◼ aortic valve stenosis ◼ heart valve prosthesis ◼ transcatheter aortic valve replacement ◼ meta-analysis Background-In

No abstract

The results of the present study do not support the assumption that hydralazine could be viewed as a "NO enhancer"; there is no evidence of attenuation of NO resistance by hydralazine treatment.